10 news items
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
RYTM
22 May 24
.] By reporting side effects, you can help provide more information on the safety of this medicine. Please see the Summary
Rhythm Pharmaceuticals Presents Data From Phase 3 Pediatrics Trial At Pediatric Endocrine Society Annual Meeting
RYTM
6 May 24
""Efficacy in Weight Reduction and Safety in Pediatric Age Groups With Rare Melanocortin-4 Receptor Pathway–Related Obesity Treated With a Therapy for 12 Months"
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
RYTM
6 May 24
""Efficacy in Weight Reduction and Safety in Pediatric Age Groups With Rare Melanocortin-4 Receptor Pathway–Related Obesity
Rhythm Pharmaceuticals Announces Publication Of Results From Phase 2 Study Of Setmelanotide For The Treatment Of Hypothalamic Obesity In The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
, and no new safety concerns were observed during the long-term extension trial.In January 2024, Rhythm announced the completion of screening
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
, no AEs that led to study discontinuation during the trial, and no new safety concerns were observed during the long-term extension trial
j2aejb xcurqh1dfx
RYTM
24 Apr 24
adverse reactions in Europe. Please see the full Prescribing Information for additional Important Safety Information
oety3sls09rdou 0ltnuq3fntz2j7pgjamxhcc1zhqhrmsr
RYTM
16 Apr 24
on reporting suspected adverse reactions in Europe. Please see the full Prescribing Information for additional Important Safety
hereqyy3awm599l04oeeuwpwbex1zvbdq7q2lerd
RYTM
25 Mar 24
- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential
gx0i q3sa7eg11m1bunzvg9ty4alpg
RYTM
11 Mar 24
for additional Important Safety Information. Forward-looking Statements This press release contains forward
a9lk7n0w
RYTM
6 Mar 24
. Please see the full Prescribing Information for additional Important Safety Information. Forward-looking Statements
- Prev
- 1
- Next